ICPT Intercept Pharmaceuticals Inc.

-0.64  -1%
Previous Close 64.64
Open 65.16
Price To Book 11.94
Market Cap 2,092,568,576
Shares 32,696,384
Volume 451,798
Short Ratio
Av. Daily Volume 649,422

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Ocaliva - Obeticholic acid (OCA) - REVERSE
NASH patients with compensated cirrhosis
Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016. Updated U.S. label for Ocaliva anticipated by early 2018
Obeticholic acid (Ocaliva)
Primary biliary cirrhosis (PBC) - POISE
NDA filing due 3Q 2019.
Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data released July 31, 2017 - primary endpoint met. Late breaker at AASLD October 23, 2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions
  2. Edited Transcript of ICPT earnings conference call or presentation 7-Aug-19 12:30pm GMT
  3. Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
  4. Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79%
  5. Intercept Pharmaceuticals Inc (ICPT) Q2 2019 Earnings Call Transcript
  6. What You'll Want to Know About Intercept Pharmaceuticals' Q2 Update
  7. Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates
  8. Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
  9. Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019
  10. Will Intercept Pharmaceuticals (ICPT) Report Negative Q2 Earnings? What You Should Know
  11. 3 Top Healthcare Stocks to Buy in July
  12. 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
  13. Better Buy: Intercept Pharmaceuticals vs. CV Sciences
  14. An Intrinsic Calculation For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Suggests It's 43% Undervalued
  15. See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
  16. ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
  17. Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor
  18. Is Intercept Pharmaceuticals Inc (ICPT) A Good Stock To Buy?
  19. CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study